Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an LSD1 inhibitor and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit or reduce progression of the cancer.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
2.
PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER
Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
5.
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 35/04 - Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
A61P 35/04 - Antineoplastic agents specific for metastasis
6.
PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER
Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 35/04 - Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
7.
CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS
Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating a PARP inhibitor (for example, olaparib) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the cancer.
A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
Disclosed herein include methods, compositions, and kits suitable for use in treating cancer in a subject. In some embodiments, the method comprises administration of onvansertib and a PART inhibitor (e.g., olaparib, niraparib, and AZD53O5) to the subject in a manner sufficient to inhibit progression of the cancer.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
10.
CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS
Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an MTDP inhibitor (for example, paclitaxel) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit or reduce progression of the cancer.
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
11.
PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER
Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
Provided includes methods, compositions and kits for improving outcome of a treatment for colorectal cancer, and methods, compositions and kits for determining responsiveness of a subject to a treatment for colorectal cancer. Determining responsiveness can comprise determining change(s) in mean level of somatic mutations of at least three genes in the subject. The treatment for colorectal cancer can comprise administering PLK1 inhibitor (e.g., onvansertib) and bevacizumab to the subject.
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
13.
CANCER TREATMENT USING TOPOISOMERASE I INHIBITORS AND PLK1 INHIBITORS
Disclosed herein include methods, compositions, and kits suitable for use in treating cancer. In some embodiments, the method comprises administrating a topoisomerase I inhibitor and onvansertib to a subject with cancer, thereby inhibiting progression of the cancer. The method can further comprise an angiogenesis inhibitor. The method can include sensitizing cancer cells to a topoisomerase I inhibitor, by contacting the cancer cells with a composition comprising onvansertib.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
Disclosed herein include methods, compositions, and kits suitable for use in treating a subject having cancer and/or determining the efficacy of treatment to a subject having a cancer. In some embodiments, the method comprises determining the presence or absence of at least one mutation in a gene encoding mechanistic target of rapamycin kinase (mTOR) in the subject; and administering onvansertib and an antiandrogen or androgen antagonist to the subject, if the at least one mutation in the mTOR gene is determined to be present in the subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Disclosed herein include methods, compositions, and kits suitable for use in treating a hematological cancer in a subject. In some embodiments, the method comprises determining the presence or absence of at least one mutation in one or more genes encoding a spliceosome protein in sample nucleic acids from the subject; and administering onvansertib and decitabine to the subject, if the at least one mutation in one or more genes encoding a spliceosome protein is determined to be present in the sample nucleic acids, thereby reducing or inhibiting progression of the hematological cancer in the subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Provided includes methods, compositions and kits for improving outcome of a cancer treatment, and methods, compositions and kits for determining responsiveness of a subject to a cancer treatment. The cancer treatment can comprise administering PLK1 inhibitor (e.g., onvansertib) to the subject.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 35/04 - Antineoplastic agents specific for metastasis
A61P 15/00 - Drugs for genital or sexual disorders; Contraceptives
17.
CIRCULATING TUMOR DNA AS A BIOMARKER FOR LEUKEMIA TREATMENT
Provided herein includes a method comprising analyzing circulating tumor DNA (ctDNA), for example ctDNA in plasma, from a patient with leukemia, to predict and/or determine clinical response. The leukemia can be, for example, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic melomonocytic leukemia (CMML).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
18.
CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS
Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an LSD1 inhibitor and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit or reduce progression of the cancer.
Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an FGFR inhibitor (for example, AZD4547) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the cancer.
Provided include methods, compositions and kits for treating a leukemia or lymphoma in a subject. The method can comprise administrating a BCL-2 inhibitor and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the leukemia or lymphoma.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
21.
CANCER TREATMENT USING PARP INHIBITORS AND PLK1 INHIBITORS
Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating a PARP inhibitor (for example, olaparib) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the cancer.
Provided is a method comprising recommending treatment of a prostate cancer patient with a polo-like kinase-1 (PLK1) inhibitor if the patient has rising prostate specific antigen (PSA) levels.
Provided is a method comprising recommending treatment of a prostate cancer patient with a polo-like kinase-1 (PLK1) inhibitor if the patient has rising prostate specific antigen (PSA) levels.
Also provided is a method comprising
measuring prostate specific antigen (PSA) levels in at least two samples from a prostate cancer patient, the samples obtained from the patient at different times; and
recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples increase over time, or
not recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples do not increase over time.
Provided is a method comprising recommending treatment of a prostate cancer patient with a polo-like kinase-1 (PLK1) inhibitor if the patient has rising prostate specific antigen (PSA) levels.
Also provided is a method comprising
measuring prostate specific antigen (PSA) levels in at least two samples from a prostate cancer patient, the samples obtained from the patient at different times; and
recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples increase over time, or
not recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples do not increase over time.
Additionally provided is a method comprising recommending treatment of a PLK1 inhibitor to a patient having a prostate cancer that has an altered androgen receptor that does not require ligand for activation.
Provided is a method of treating benign prostatic hyperplasia (BPH) in a patient. Also provided is a method of inhibiting non-adrenergic contraction of a smooth muscle. Additionally provided is a method of inhibiting proliferation of human prostate cells.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 13/08 - Drugs for disorders of the urinary system of the prostate
24.
SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES
Certain molecular characteristics of cancer cells or tumors can be indicative of their sensitivity to various combination therapies. The cancer cells or tumors exhibiting such molecular profiles, such as upregulation of genes associated with mitosis or meiosis, can be sensitive to additive and more than additive effects of combination therapies. Methods for identifying, selecting, and/or treating cancer patients whose cancer is amenable to combination therapies including an antiandrogen or androgen antagonist in combination with a Plk inhibitor are disclosed. Administration of the combination of the active agents can reduce cancer cell proliferation or viability and/or tumor burden in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
25.
SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES
Certain molecular characteristics of cancer cells or tumors can be indicative of their sensitivity to various combination therapies. The cancer cells or tumors exhibiting such molecular profiles, such as upregulation of genes associated with mitosis or meiosis, can be sensitive to additive and more than additive effects of combination therapies. Methods for identifying, selecting, and/or treating cancer patients whose cancer is amenable to combination therapies including an antiandrogen or androgen antagonist in combination with a Plk inhibitor are disclosed. Administration of the combination of the active agents can reduce cancer cell proliferation or viability and/or tumor burden in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided includes methods, compositions and kits for improving outcome of a cancer treatment, and methods, compositions and kits for determining responsiveness of a subject to a cancer treatment. The cancer treatment can comprise administering PLK1 inhibitor (e.g., onvansertib) to the subject.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
27.
TREATMENT OF LEUKEMIAS AND LYMPHOMAS WITH COMBINATIONS OF BCL-2 INHIBITORS AND PLK1 INHIBITORS
Provided include methods, compositions and kits for treating a leukemia or lymphoma in a subject. The method can comprise administrating a BCL-2 inhibitor and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the leukemia or lymphoma.
Provided is a method comprising determining polo-like kinase 1 (PLK1) activity in a cancer in a patient by measuring phosphorylation of a PLK1 target (a) prior to treatment of (i) the patient or (ii) a cancer sample from the patient with a PLK1 inhibitor, and (b) after the treatment.
Provided is a method comprising determining polo-like kinase 1 (PLK1) activity in a cancer in a patient by measuring phosphorylation of a PLK1 target (a) prior to treatment of (i) the patient or (ii) a cancer sample from the patient with a PLK1 inhibitor, and (b) after the treatment.
Also provided is a method comprising determining polo-like kinase 1 (PLK1) activity in a cancer in a patient by measuring phosphorylation of a PLK1 target without treatment with a PLK1 inhibitor.
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
C12Q 1/6804 - Nucleic acid analysis using immunogens
29.
CIRCULATING TUMOR DNA AS A BIOMARKER FOR LEUKEMIA TREATMENT
Provided herein includes a method comprising analyzing circulating tumor DNA (ctDNA), for example ctDNA in plasma, from a patient with leukemia, to predict and/or determine clinical response. The leukemia can be, for example, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic melomonocytic leukemia (CMML).
A61P 35/02 - Antineoplastic agents specific for leukemia
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Provided is a method comprising recommending treatment of a prostate cancer patient with a polo-like kinase- 1 (PLK1) inhibitor if the patient has rising prostate specific antigen (PSA) levels. Also provided is a method comprising measuring prostate specific antigen (PSA) levels in at least two samples from a prostate cancer patient, the samples obtained from the patient at different times; and recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples increase over time, or not recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples do not increase over time. Additionally provided is a method comprising recommending treatment of a PLK1 inhibitor to a patient having a prostate cancer that has an altered androgen receptor that does not require ligand for activation.
Provided is a method of treating benign prostatic hyperplasia (BPH) in a patient. Also provided is a method of inhibiting non- adrenergic contraction of a smooth muscle. Additionally provided is a method of inhibiting proliferation of human prostate cells.
A61P 13/08 - Drugs for disorders of the urinary system of the prostate
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61P 13/02 - Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
C07H 15/224 - Cyclohexane rings, substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexane rings, e.g. destomycin, fortimicin, neamine
C07H 15/236 - Cyclohexane rings, substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2 a saccharide radical being substituted by an alkylamino radical in position 3 and by two substituents different from hydrogen in position 4, e.g. gentamicin complex, sisomicin, verdamicin
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical research and development.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical research and development.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical research and development.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical research and development
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of cancer; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical research and development
37.
Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media
This invention provides compositions and methods for rapid separation, isolation and purification of nucleic acids from biological samples using anionic exchange media. The method can utilize commercially available strong or weak anion exchanger materials with selected solutions of known ionic strength for adsorption and elution. The instant method is particularly advantageous as it permits the purification and identification of shorter fragments of nucleic acids from bodily fluids which, until now, had not been identified.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
38.
Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof
The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML).
The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML).
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
40.
Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media
This invention provides compositions and methods for rapid isolation and purification of nucleopolymers from biological samples using anionic exchange media. The method of this invention can utilize commercially available anion exchanger materials with selected solutions of known ionic strength for absorption and elution. The medium/nucleoprotein bound complex may be optionally stored or transported, and is subsequently treated with eluents to remove undesirable proteins and inorganic salts. The partially purified complex may also be stored or transported. This method is particularly advantageous since it allows rapid isolation and purification of soluble nucleic acids from a large volume of biological fluids with easy handling and storage, stabilizing the samples against degradation prior to analysis. It also permits the purification and identification of shorter fragments of nucleic acids from bodily fluids which, until now, had not been identified. The method is widely useful to prepare samples formats that are convenient in diagnostic analytical methods.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
